Biomarker Identification in Patients with Multiple Sclerosis Treated with Autologous Hematopoietic Stem Cell Transplantation
Introduction: Approximately 80% of individuals with multiple sclerosis (MS) have a positive response to autologous hematopoietic stem cell transplantation (aHSCT). Markers that may predict the transplant outcome are necessary. The objective of this work is to identify markers that may refine the sel...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2025-03-01
|
| Series: | Sclerosis |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2813-3064/3/2/9 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849432260110974976 |
|---|---|
| author | Moisés Manuel Gallardo-Pérez Alejandro Ruiz-Argüelles Guillermo José Ruiz-Argüelles Virginia Reyes-Núñez Silvia Soto-Olvera Solón Javier Garcés-Eisele |
| author_facet | Moisés Manuel Gallardo-Pérez Alejandro Ruiz-Argüelles Guillermo José Ruiz-Argüelles Virginia Reyes-Núñez Silvia Soto-Olvera Solón Javier Garcés-Eisele |
| author_sort | Moisés Manuel Gallardo-Pérez |
| collection | DOAJ |
| description | Introduction: Approximately 80% of individuals with multiple sclerosis (MS) have a positive response to autologous hematopoietic stem cell transplantation (aHSCT). Markers that may predict the transplant outcome are necessary. The objective of this work is to identify markers that may refine the selection of patients with multiple sclerosis who could benefit from aHSCT. Methods: We evaluated the levels of six biomarkers in the peripheral blood of patients with MS before aHSCT. The design of this study is cross-sectional; patients were divided into two transplant-responses-at-12-months groups, responders (ΔEDSS < 0) and non-responders (ΔEDSS > 0). Pre-transplant samples were used to assess the different markers. Results: Thirty-four patients were enrolled: fourteen were non-responders and twenty were responders to aHSCT. Among the evaluated biomarkers, a significant difference was only detected in miR-146a levels, with increased values in the non-responder group. Conclusions: The biomarker miR146a could be useful to evaluate the response to aHSCT in patients with MS. |
| format | Article |
| id | doaj-art-3e9c1f58e8de4b5daf6956d37c81ef00 |
| institution | Kabale University |
| issn | 2813-3064 |
| language | English |
| publishDate | 2025-03-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Sclerosis |
| spelling | doaj-art-3e9c1f58e8de4b5daf6956d37c81ef002025-08-20T03:27:25ZengMDPI AGSclerosis2813-30642025-03-0132910.3390/sclerosis3020009Biomarker Identification in Patients with Multiple Sclerosis Treated with Autologous Hematopoietic Stem Cell TransplantationMoisés Manuel Gallardo-Pérez0Alejandro Ruiz-Argüelles1Guillermo José Ruiz-Argüelles2Virginia Reyes-Núñez3Silvia Soto-Olvera4Solón Javier Garcés-Eisele5Department of Biotechnology, Universidad Popular Autónoma del Estado de Puebla, Puebla 72410, MexicoDepartment of Biotechnology, Universidad Popular Autónoma del Estado de Puebla, Puebla 72410, MexicoDepartment of Biotechnology, Universidad Popular Autónoma del Estado de Puebla, Puebla 72410, MexicoLaboratorios Ruiz, SYNLAB Mexico, Puebla 72530, MexicoDepartment of Biotechnology, Universidad Popular Autónoma del Estado de Puebla, Puebla 72410, MexicoDepartment of Biotechnology, Universidad Popular Autónoma del Estado de Puebla, Puebla 72410, MexicoIntroduction: Approximately 80% of individuals with multiple sclerosis (MS) have a positive response to autologous hematopoietic stem cell transplantation (aHSCT). Markers that may predict the transplant outcome are necessary. The objective of this work is to identify markers that may refine the selection of patients with multiple sclerosis who could benefit from aHSCT. Methods: We evaluated the levels of six biomarkers in the peripheral blood of patients with MS before aHSCT. The design of this study is cross-sectional; patients were divided into two transplant-responses-at-12-months groups, responders (ΔEDSS < 0) and non-responders (ΔEDSS > 0). Pre-transplant samples were used to assess the different markers. Results: Thirty-four patients were enrolled: fourteen were non-responders and twenty were responders to aHSCT. Among the evaluated biomarkers, a significant difference was only detected in miR-146a levels, with increased values in the non-responder group. Conclusions: The biomarker miR146a could be useful to evaluate the response to aHSCT in patients with MS.https://www.mdpi.com/2813-3064/3/2/9biomarkersmultiple sclerosisauto-HSCT |
| spellingShingle | Moisés Manuel Gallardo-Pérez Alejandro Ruiz-Argüelles Guillermo José Ruiz-Argüelles Virginia Reyes-Núñez Silvia Soto-Olvera Solón Javier Garcés-Eisele Biomarker Identification in Patients with Multiple Sclerosis Treated with Autologous Hematopoietic Stem Cell Transplantation Sclerosis biomarkers multiple sclerosis auto-HSCT |
| title | Biomarker Identification in Patients with Multiple Sclerosis Treated with Autologous Hematopoietic Stem Cell Transplantation |
| title_full | Biomarker Identification in Patients with Multiple Sclerosis Treated with Autologous Hematopoietic Stem Cell Transplantation |
| title_fullStr | Biomarker Identification in Patients with Multiple Sclerosis Treated with Autologous Hematopoietic Stem Cell Transplantation |
| title_full_unstemmed | Biomarker Identification in Patients with Multiple Sclerosis Treated with Autologous Hematopoietic Stem Cell Transplantation |
| title_short | Biomarker Identification in Patients with Multiple Sclerosis Treated with Autologous Hematopoietic Stem Cell Transplantation |
| title_sort | biomarker identification in patients with multiple sclerosis treated with autologous hematopoietic stem cell transplantation |
| topic | biomarkers multiple sclerosis auto-HSCT |
| url | https://www.mdpi.com/2813-3064/3/2/9 |
| work_keys_str_mv | AT moisesmanuelgallardoperez biomarkeridentificationinpatientswithmultiplesclerosistreatedwithautologoushematopoieticstemcelltransplantation AT alejandroruizarguelles biomarkeridentificationinpatientswithmultiplesclerosistreatedwithautologoushematopoieticstemcelltransplantation AT guillermojoseruizarguelles biomarkeridentificationinpatientswithmultiplesclerosistreatedwithautologoushematopoieticstemcelltransplantation AT virginiareyesnunez biomarkeridentificationinpatientswithmultiplesclerosistreatedwithautologoushematopoieticstemcelltransplantation AT silviasotoolvera biomarkeridentificationinpatientswithmultiplesclerosistreatedwithautologoushematopoieticstemcelltransplantation AT solonjaviergarceseisele biomarkeridentificationinpatientswithmultiplesclerosistreatedwithautologoushematopoieticstemcelltransplantation |